natgillin/translations-raw huggingface dataset:
A compound represented by the following formula (I) or a pharmaceutically acceptable acid addition salt thereof: wherein R is a hydrogen atom or a C1-6 alkyl group optionally substituted with 1 to 3 fluorine atoms, wherein when R is a hydrogen atom, 
Spoj predstavljen sa slijedećom formulom (I) ili njegova farmaceutski prihvatljiva kisela adicijska sol: pri čemu R je vodikov atom ili skupina C1-6 alkil proizvoljno supstituirana s 1 do 3 fluorovih atoma, pri čemu kada R je vodikov atom,
the conveyor belt or the shaker conveyor (2) is started up so as to provide a flow of solid in the range 150 kg/h to 500 kg/h, preferably in the range 250 kg/h to 500 kg/h, said solid particles being introduced into the annular zone (4) via the rigid auxiliary tube (7); 
* pokreće se transportna traka ili tresući transporter (2) tako da se osigura strujanje krutih čestica u rasponu od 150 kg/h do 500 kg/h, poželjno u rasponu od 250 kg/h do 500 kg/h, navedene krute čestice se uvode u prstenastu zonu (4) preko krute pomoćne cijevi (7),
Chitin is a natural substance constituting, for example, the carapace of crustaceans and many insects. 
Hitin je prirodna tvar koja tvori, na primjer, leđni oklop rakova i mnogih kukaca.
Stirring at +4° C. was continued for an hour, then DIPEA (2 eq) and Boc-piperazine (1 eq) were added and the mixture was left to warm to room temperature, under stirring. 
Miješanje pri +4T je nastavljeno jedan sat te su dodani DIPEA (2 ekviv.) i Boc-piperazin (1 ekviv.) i smjesa je ostavljena da se ugrije do sobne temperature uz miješanje.
The method of claim 13, wherein the nucleoside analog is selected from among fluoropyrimidine 5-fluorouracil, 5-fluoro-2′-deoxycytidine, cytarabine, gemcitabine, troxacitabine, decitabine, Azacytidine, pseudoisocytidine, Zebularine, Ancitabine, Fazarabine, 6-azacytidine, capecitabine, N4-octadecyl-cytarabine, elaidic acid cytarabine, fludarabine, cladribine, clofarabine, nelarabine, forodesine, and pentostatin, or derivatives thereof. 
Kombinacija ili kompozicija za upotrebu prema bilo kojem od patentnih zahtjeva 5-14, naznačena time što je nukleozidni analog odabran između fluoropirimidin 5-fluorouracila, 5-fluoro-2’-deoksicitidina, citarabina, gemcitabina, troksacitabina, decitabina, azacitidina, pseudoizocitidina, zebularina, ancitabina, fazarabina, 6-azacitidina, kapecitabina, N4-oktadecil-citarabina, citarabina elaidinske kiseline, fludarabina, kladribina, klofarabina, nelarabina, forodesina i pentostatina, ili njihovih derivata.
The method of claim 5, wherein said sugar is glycerol, sorbitol, or sucrose. 
Postupak sukladno patentnom zahtjevu 5, naznačeno time, da je spomenuti šećer glicerol, sorbitol, ili saharoza.
Wind system (1) for converting energy, comprising: at least one kite (2) adapted to be driven from ground immersed in at least one wind current (W); 
HR P20150861 T1 PATENTNI ZAHTJEVI Vjetreni sustav (1) za konvertiranje energije koji uključuje: najmanje jednog zmaja (2) koji je prilagođen na način da se uzgoni sa zemlje uronjen u najmanje jednu struju vjetra
wherein when R1 is C1-2alkyl, said C1-2alkyl is optionally substituted with one to two substituents independently selected from the group consisting of C1-6alkoxy, aryl, cycloalkyl, heterocyclyl, hydroxy, cyano, amino, C1-6alkylamino, (C1-6alkyl)2amino, trifluoromethyl, and carboxy; 
R'' supstituenta nezavisno izabrana iz skupine koju čine C,.galkoksi; heteroaril proizvoljno supstituiran sa jednim do dva supstituenta nezavisno izabrana iz skupine koju čine C,galkil, Crgalkoksi, te karboksi; karboksi; Ciaalkoksikarbonil; C,4alkoksikarboniloksi; aminokarbonil; C,ualkilaminokarbonil; C.gcikloalkilaminokarbonil; hidroksi(Ci.g)alkilaminokarbonil; Cg.joarilaminokarbonil pri čemu C4.aril je proizvoljno supstituiran sa karboksi ili
is selected from N and CR7; wherein R7 is selected from hydrogen and C1-4alkyl; 
Y, je odabran od N i CRy; pri čemu je R; odabran od vodika i C,aalkila;
Use of a compound according to any one of claims 1-13 or a pharmaceutically acceptable derivate thereof for the manufacture of a medicament useful for treating pain, a memory disorder, obesity, constipation, urinary incontinence, anxiety, cough, diarrhea, high blood pressure, epilepsy, anorexia/cachexia, or drug abuse in an animal, and wherein the pharmaceutically acceptable derivative is selected from the group consisting of pharmaceutically acceptable salt, solvate, radiolabeled, stereoisomer, enantiomer, diastereomer, other stereoisomeric form, racemic mixture, geometric isomer, and/or tautomer. 
Upotreba spoja prema bilo kojem zahtjevu od 1 do 19, naznačena time da je za proizvodnju lijeka korisnog za liječenje boli, poremećaja pamćenja, pretilosti, konstipacije, urinarne inkontinencije, anksioznosti, kašlja, dijareje, visokog krvnog tlaka, epilepsije, anoreksije/kaheksije, ili zloupotrebe droge kod životinja.
The gown according to claim 1 wherein at least one elastic strip, positioned in the shoulder area of a user, traverses the gown opening and is permanently attached to the right side portion and to the left side portion of the back of the gown on each side of the gown opening. 
Kuta prema zahtjevu 2, naznačena time, da se najmanje jedna elastična traka (7) u području ramena korisnika nalazi, koja otvor popreko prolazi i sa desnim dijelom kao i sa lijevim dijelom leđa kute je na svakoj strani otvora spojena.
The system of claim 7, wherein the control system is arranged and configured to receive information regarding the turbidity of the water and to activate the flocculant application to adjust the turbidity within a set limit. The system of claim 1, wherein the bottom of the container has a color that provides a specific coloration to water in the water body. The system of claim 1, wherein the bottom of the container has a white, yellow, or light blue color. 
Postupak prema zahtjevu 1, naznačen time što kontrolni sustav prima informacije o boji dna vodenog tijela i aktivira rad usisnog uređaja kako bi se podesila boja unutar zadanih granica. Postupak prema zahtjevu 1, naznačen time što kontrolni sustav prima informacije o količini plutajućih masnih tvari i aktivira rad sustava za odmašćivanje kako bi podesio količinu plutajućih masti unutar zadanih granica.
A window casing comprising: a fixed frame (1) comprising a first jamb (11a) and a second jamb (11b); 
- < fiksni okvir (1) koji sadržava prvu okomitu gredu dovratka (11a) i drugu okomitu gredu dovratka (11b);
Method as in any claim hereinbefore, the method providing to add an anti-coagulant to the blood sample. 
Postupak prema bilo kojem prethodnom zahtjevu, naznačen time što postupak predviđa dodavanje anti-koagulanta u uzorak krvi.
a sealing step (108) with a heat-sealing process of said vacuum bag (2) containing said bulk goods (3) to maintain said internal vacuum pressure and isolation of said bulk goods (3) from the external environment. 
korak varenja (108) termičkim postupkom te vakuum vrećice (2) koja sadrži rasuti proizvod (3) radi održavanja unutarnjeg vakuuma i izolacije rasutog proizvoda (3) od vanjskog okoliša.
Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. 
Oralni tekući pripravci mogu biti u obliku, primjerice, vodenih ili uljnih suspenzija, otopina, emulzija, sirupa ili ljekovitih napitaka, ili ih se može davati u obliku suhog proizvoda za pripravu s vodom, ili kojim drugim pogodnim vehikulumom, prije upotrebe.
Generally, these can be antibodies (especially monoclonal antibodies) or a fragment of an antibody that contains at least one binding site, lymphokines, hormones, growth factors, nutrient-transport molecules (such as transferrin), or any other cell binding molecule or substance. 
Konjugat u skladu s patentnim zahtjevom 3 do 7 naznačen time što se navedeno sredstvo za vezanje na stanicu bira između protutijela ili fragmenta protutijela koji sadrži najmanje jedno vežuće mjesto, limfokina, hormona, čimbenika rasta, molekula za prijenos nutrijenata ili bilo koje druge molekule ili tvari koja se veže na stanicu.
a stream of ethane is subjected to a catalytic oxydehydrogenation producing a gas mixture containing ethylene, unconverted ethane, water and secondary constituents; said gas mixture is optionally washed and dried thus producing a dry gas mixture; after an optional additional purification step, the dry gas mixture is then conveyed to a chlorination reactor supplied with a flow of chlorine so that at least 10% of the ethylene is converted to 1,2-dichloroethane; 
Postupak za proizvodnju vinil klorida naznačen time da: a) struja etana je podvrgnuta katalitičkoj oksidehidrogenaciji koja daje plinsku mješavinu koja sadrži etilen, nepretvoreni etan, vodu i sekundarne sastojke; b) navedena plinska mješavina se proizvoljno ispire i suši te se tako dobiva suha plinska mješavina; C) nakon proizvoljnog dodatnog koraka pročišćavanja, suha plinska mješavina se tada prebacuje u reaktor za kloriranje u koji se dovodi struja klora tako da je barem 10% etilena pretvoreno u 1,2-dikloroetan; d) 1,2-dikloroetan dobiven u reaktoru za kloriranje je proizvoljno izoliran iz struje produkata dobivenih iz reaktora za kloriranje;
Process according to Claim 1, wherein it further comprises a step f) of stopping the crosslinking, said step f) being carried out prior to, together with or subsequent to the recovery step e). 
Postupak prema zahtjevu 1, naznačen time da nadalje sadrži korak f) zaustavljanja umrežavanja, navedeni korak f) se provodi prije, zajedno s ili nakon koraka obnavljanja €).
This object of the present invention has been surprisingly solved in one aspect by providing a microorganism as a carrier of nucleotide sequences coding for antigens and protein toxins comprising the following components: 
PATENTNI ZAHTJEVI L Mikroorganizam kao nosač nukleotidnih odsječaka koji kodiraju antigene i proteinske toksine, naznačen time, da sadrži sljedeće sastavne dijelove:
heating the solution resulting from step (i) to a temperature of 50-100°C for 0.15 to 30 minutes; 
zagrijavanje otopine dobivene u koraku (i) do temperature od 50 do kroz 0.15 do 30 minuta;
A delayed release drug formulation as claimed in any of Claims 1 to 4, wherein said inner layer comprises at least one additive selected from a buffer agent and a base. 
Formulacija lijeka s odloženim otpuštanjem sukladno patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačeno time, da unutarnji sloj sadrži najmanje jedno pufersko sredstvo i najmanje jednu bazu.
8.2 TABLE 7b pH stability of Alkaloid (nicotine) containing Lozenges with Citrate 
Tabela 7hb pH stabilnost tableta koje sadrže alkaloid (nikotin) sa citratnim puferom čuvane na 40%C/75% relativne vlažnosti
A process of manufacturing apixaban tablets as defined in claim 8, wherein the dissolution properties are established as an average of 6 tablets. 
Postupak proizvodnje tableta apiksabana kao što je definirano u patentnom zahtjevu 8, pri čemu su svojstva otapanja utvrđena kao prosjek od 6 tableta.
represents a C1-4 alkoxy carbonyl group, a C3-6 cycloalkyl group, a benzoyl group or a C1-3 alkyl group optionally substituted by 1 to 4 substituents selected from a halogen atom or a hydroxyl group; and/or 
R4 predstavlja C,2 alkoksikarbonilnu skupinu, C34 cikloalkilkarbonilnu skupinu, benzoilnu skupinu ili C,.g alkilnu skupinu, izborno supstituiranu s 1 do 4 supstitucnta, koje sc bira između atoma halogena ili hidroksilne skupinc; i/ili
preparing a solution of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(B-D-glucopyranos-1-yl)-benzene and the one or more natural amino acids in a solvent or a mixture of solvents; 
(a) pripravljanje otopine od 1-cijano-2-(4-ciklopropil-benzil)-4-(B-D-glukopiranoz-1-il)-benzena i jedne ili više prirodnih aminokiselina u jednom otapalu ili u mješavini otapala;
The pyridine derivative or the pharmaceutically acceptable salt thereof, according to claim 1, wherein Z is Z1, and R6 and R7 are, on a phenyl ring, chlorine substituents at 2- and 5-positions, chlorine substituents at 3- and 5-positions, methyl substituents at 2- and 5-positions, trifluoromethyl substituents at 2- and 5-positions, or chlorine and methyl substituents at 2- and 5-positions, respectively; or 
Derivat piridina ili njegova farmaceutski prihvatljiva sol, ili njegov solvat prema zahtjevu 12, naznačen time da Z je Z1, 1 R 1 Ri su, na fenilnom prstenu, klorovi supstituenti na 2- i 5-položaju, klorovi supstituenti na 3- i 5- položaju, metilni supstituenti na 2- i 5-položaju, trifluorometil supstituenti na 2- i 5-položaju, ili odgovarajući klorovi i metilni supstituenti na 2- i 5-položaju;
Therefore, this arrangement can be used to achieve orthogonal flow through the microfluidic arrangement 1 as seen from the outside, in contrast to the lateral flow in the example according to the first embodiment which was described above. 
Zbog toga se tu napravu može upotrijebiti za provedbu okomitog protoka kroz mikrofluidnu napravu 1, kako se vidi izvana, suprotno bočnom protoku u primjeru prema prvoj izvedbi koja je bila gore opisana.
oo. 005-C04-58-33-1 comprises a variable heavy chain domain corresponding to a nucleic acid sequence according to SEQ ID NO: 414, and an amino acid sequence according to SEQ ID NO: 226, and a variable light chain domain with a nucleic acid sequence according to SEQ ID NO: 486, and an amino acid sequence according to SEQ ID NO: 298, 
-H08-65-33-2 sadrži promjenjivu domenu teškog lanca koja odgovara sekvenci nukleinske kiseline u skladu sa SEQ ID NO: 351, te sekvencu nukleinske kiseline u skladu sa SEQ ID NO: 163, i promjenjivu domenu lakog lanca sa sekvencom nukleinske kiseline u skladu sa SEQ ID NO: 373, te sekvencu nukleinske kiseline u skladu sa SEQ ID NO: 185,
A method for producing an aripiprazole suspension comprising the steps of: 
Postupak za proizvodnju suspenzije aripiprazola koji sadrži korake:
Device according to claim 16, wherein the controller generates a systematic cleaning profile of the bed of the body of water and ensures that the suction module cleans the required sites on the bed of the body of water at least once. 
Uređaj sukladno zahtjevu 16, naznačen time što kontroler generira sistematsko čišćenje dna vodene površine i osigurava da usisni modul (11) čisti potrebna mjesta dna vodene površine barem jednom.
In other embodiments, the coated paper products comprising a co-processed microfibrillated cellulose and inorganic particulate material composition may have a lower moisture vapour transmission rate (MVTR, tested in accordance with a modified version of TAPPI T448 using silica gel as the desiccant and a relative humidity of 50%) as compared to the coated paper product devoid of the co-processed microfibrillated cellulose and inorganic particulate material composition. 
Artikl u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što papirni proizvod sadrži od otprilike 0,5%, težinski, do otprilike 50%, težinski, suobrađene mješavine mikrofibrilirane celuloze i anorganskog partikuliranog materijala, primjerice od otprilike 25%, težinski, do otprilike 35%, težinski, suobrađene mješavine mikrofibrilirane celuloze i anorganskog partikuliranog materijala.
The cartridge of claim 1, wherein for each data field grouping, the partition map comprises a byte having a bit identifying the encryption attribute of the at least one data field grouping and at least two bits identifying the access mode of the at least one data field grouping. 
Patrona (24) u skladu s patentnim zahtjevom 1, naznačena time što kod svake grupacije podatkovnih polja particijska mapa (52) sadrži bajt koji sadrži bit koji identificira enkripcijski atribut za najmanje jednu od grupacija podatkovnih polja i najmanje dva bita koji identificiraju pristupni način za najmanje jednu od grupacija podatkovnih polja.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of general formula (I) and/or a salt or stereoisomer thereof as defined in any one of claims 1 - 10 . 
Farmaceutski pripravak, naznačen time da sadrži farmaceutski prihvatljiv nosač i farmaceutski učinkovitu količinu spoja opće formule (21) ifili njegove soli ili stereoizomera kao što je definirano u patentnim zahtjevima 1-6.
The method of claim 1, wherein the proportion of impaired pixels in the hit frame (xl_i) is calculated based on the number of bytes of video lost due to the loss event i in the current hit frame (blp_i) divided by the number of lost and correctly received bytes in the current hit frame (bp) using the relation xl_i=blp_i/bp. 
Metoda prema zahtjevu 1 ili 2, naznačena time, da se udio oslabljenih piksela u zadanom okviru xl_i izračunava na temelju broja bitova videozapisa izgubljenih zbog događaja i gubitka u trenutnom zadanom okviru bip_i, podijeljen brojem izgubljenih i pravilno primljenih bitova u trenutnom zadanom okviru, bp, koristeći relaciju xl_1 = blp_i/bp.
After applying the PG solution to the column, a protein peak, peak 2 in FIG. 1 (detected at A280), was eluted from the column and was found to contain the r-hIL-18BP (detected by ELISA). 
Nakon nanošenja otopine PG-a na kolonu, sa kolone je eluiran proteinski peak, peak 2 na Slici 1 (detekcija na A280), za kojeg je utvrđeno da sadržava r-hIL-18BP (detektirano ELISA testom).
wherein R1 is as defined in formula (I); or reaction of a compound of formula (XI) 
4 gdje je R! kako je definirano u formuli (1); ili Cc) reakciju spoja formule (XI) 2
type I lesions (previously known as sympathetic reflex dystrophy); and type II lesions (corresponding approximately to causalgia); or whereby the predominantly central neuropathic pain is of a type that has a cause that is selected from the following group of causes: 
- lezije tipa I (prethodno poznate kao simpatička refleksna distrofija); i - lezije tipa II (koje približno odgovaraju kauzalgiji); ili pri čemu je pretežno središnja neuropatska bol tipa koja ima uzrok koji je odabran iz slijedeće skupine uzroka:
is H, or a group mentioned for R4; 
R? je H, ili grupa navedena za R*;
the amino acid sequence has a Aspartic acid (Asp, D) at position 1 (said position determined according to Kabat numbering); and ii) the amino acid sequence binds protein F of hRSV with the same, about the same, or a higher affinity (said affinity as measured by surface plasmon resonance) and/or the amino acid sequence has the same, about the same, or a higher potency (as defined herein) compared to the amino acid sequence without the 3, 2 or 1 amino acid difference. 
sekvenca amino kiseline ima Glutamin (Gln, Q) na položaju 105, pri čemu se navedeni položaj određuje prema Kabatovom numeriranju; i ii) sekvenca amino kiseline veže protein F iz hRSV s istim ili višim afinitetom, pri čemu se navedeni afinitet mjeri površinskom plazmonskom rezonancijom, i/ili sekvenca amino kiseline ima istu ili višu potentnost, pri čemu se navedena potentnost određuje pomoću analize mikroneutralizacije, u usporedbi sa sekvencom amino kiseline bez 3, 2 ili 1 razlikom u aminokiselini,
HCl (22 mmol) was added and the aqueous phase was extracted with ethyl acetate. 
Doda se HCI (22 mmol) i vodena faza se ekstrahira sa etil acetatom.
Animals were chronically implanted with cortical and muscle electrodes to record EEG and EMG respectively, to allow monitoring their sleep-wake cycle. 
Životinjama su kronično implantirane kortikalne odnosno mišićne elektrode, kako bi se mogao pratiti njihov ciklus spavanja i budnosti.
reacting compound (7) and compound (8) to provide a compound of formula I: 
(c) reagiranje spoja (7) i spoja (8) čime se dobiva spoj formule I: č
the first compound is a neuropharmaceutical for mitigating one or more of said symptoms; and the second compound is sorbic acid, a sorbic acid salt or a sorbic acid derivative, wherein the sorbic acid salt is selected from the group consisting of sodium sorbate, potassium sorbate, and calcium sorbate; the sorbic acid derivative is selected from the group consisting of sorbohydroxamic acid, sorbic aldehyde, sorbic acid-thiol adduct, 8-quinolinylsorbate, and m-nitrosorbanilide; and the amount of the second compound is sufficient to increase the efficacy of said first compound and ranges from about 5 mg to about 500 g. 
HR P20170089 T1 PATENTNI ZAHTJEVI Sastav za uporabu u metodi ublažavanja jednog ili više simptoma shizofrenije, koji karakterizira to da sastav sadrži djelatne količine prvog i drugog aktivnog sastojka, na način da je prvi sastojak antipsihotik, a drugi sastojak je benzojeva kiselina ili sol benzojeve kiseline, pri čemu se sol benzojeve kiseline bira iz skupine koja se sastoji od natrijevog benzoata, kalijevog benzoata, kalcijevog benzoata i litijevog benzoata i pri čemu je količina benzojeve kiseline ili soli benzojeve kiseline dovoljna za povećanje djelotvornosti spomenutog antipsihotika i varira od približno 5 mg do približno 500 g.
The pharmaceutical dosage formulation of claim 1, wherein the formulation is present in a solid dosage form. 
Farmaceutska dozna formulacija iz patentnog zahtjeva 1, naznačena time što je formulacija čvrsti dozni oblik.
Without limitation, examples of stringent conditions include washing conditions 12-20°C below the calculated Tm of the hybrid under study in, e.g., 2 x SSC and 0.5% SDS for 5 minutes, 2 × SSC and 0.1% SDS for 15 minutes; 0.1 x SSC and 0.5% SDS at 37°C for 30-60 minutes and then, a 0.1 x SSC and 0.5% SDS at 68°C for 30-60 minutes. 
Bez ograničenja, primjeri striktnih uvjeta uključuju ispiranje pri 12-20"C ispod izračunate Tm hibrida koji se proučava u, pr. 2X SSC 10.5% SDS tijekom 5 minuta, 2X SSC i 0.1% SDS tijekom 15 minuta; 0.1X SSC i 0.5% SDS pri 37"C tijekom 30-60 minuta i nakon toga 0.1X SSC i 0.5% SDS pri 68"C tijekom 30-60 minuta.
A pharmaceutical composition comprising a compound having the structure shown in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, for use in the treatment of a disease or disorder which is selected from multiple myeloma, glioblastoma, and lymphoma. Use of a compound having the structure shown in claim 1 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating a disease or disorder selected from multiple myeloma, glioblastoma, and lymphoma. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak gušterače. Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak kože. Uporaba spoja prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju lijeka za liječenje bolesti ili poremećaja povezanih sa nekontroliranim, nenormalnim i/ili neželjenim staničnim djelovanjima.
Composition, a method for preparing said composition, a method for preparing a rigidified fabric, the rigidified fabric so obtained, a filtration device, methods for the manufacture of the filtration device, installation, process and use of said filtration device for the filtration of a liquid metal or an alloy thereof 
PRIPRAVAK, METODA ZA PRIPREMU NAVEDENOG PRIPRAVKA, METODA ZA PRIPREMU OČVRSNUTE TKANINE, OČVRSNUTE TKANINE TAKO DOBIVENE, UREĐAJ ZA FILTRACIJU, METODE ZA IZRADU UREĐAJA ZA FILTRACIJU, INSTALACIJA, PROCES | UPORABA NAVEDENOG UREĐAJA ZA FILTRACIJU ZA FILTRACIJU TEKUĆEG METALA ILI NJEGOVE
The filtration device of any one of claims 3 to 9, wherein the heat resistant fibers are made of E-Glass, S-Glass or High Silica Glass. 
Tkanina u skladu s bilo kojim od patentnih zahtjeva od 4 do 10, pri čemu su vlakna otporna na toplinu izrađena od od E-stakla, S-stakla ili visokotemperaturnog silicijskog stakla.
The method of claim 14, wherein the composition is administered to pigs at 3 weeks of age or older. 
Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 9 do 11, naznačen time što se pripravak primjenjuje na praščićima starim 3 tjedna ili starijim.